巴西卫生部最新数据显示，巴西2024年报告了超过650万例登革热疑似病例，逾6300人死亡。进入2025 年后，疫情虽有所缓解，但截至11月22日，疑似病例仍超过163万例。 （文章来源：新华社） 克福里指出，与目前巴西使用的进口两剂疫苗相比，这款疫苗在保护效果上相当，但仅需接种一剂，更 有利于提高疫苗覆盖率。 公报说，为扩大产能，布坦坦研究所已与一家中国企业达成合作，预计到2026年下半年可供应约3000万 剂疫苗。该疫苗有望纳入巴西国家免疫计划，但具体接种时间和适用年龄段仍待政府决定。 布坦坦研究所所长埃斯珀·卡拉斯表示，这是巴西科学和卫生事业的历史性突破，"一种困扰我们几十年 的疾病，如今终于可以用一剂强效疫苗解决。" 巴西布坦坦研究所26日发布新闻公报称，该所研发的一款登革热疫苗已获巴西卫生监督局批准，可用于 12至59岁人群。该疫苗是世界首款单剂登革热疫苗。 巴西免疫学会副会长雷纳托·克福里在接受当地媒体采访时表示，该疫苗展现出良好的保护效果：总有 效率接近75%，预防重症的有效率超过90%。 ...

每经记者｜陈星 实习生 范芊芊 每经编辑｜文多 4月10日，2021全国疫苗与健康大会在成都召开。国家卫生健康委医药卫生科技发展研究中心主任、国 务院联防联控机制科研攻关组疫苗研发工作组组长郑忠伟参与了"由新冠疫苗看中国疫苗创新"为主题的 圆桌访谈。他表示，对于中国疫苗研发，在坚定自信的同时，也要了解不足。 "从此次新冠疫苗研发来看，我们所有的中国人既要有中国自信，也要有中国冷静。"他说。 封面图片来源：摄图网 他指出，在生物医药领域，我国有一些国家优势，包括体制、组织、文化优势；而不足则体现在基础研 究、载体平台、组织研发等方面，尤其在国际临床项目上与国外差距明显。 那么国际临床项目上的差距如何补足？他说，"十四五"期间，国家大概要投入40亿元左右用于推进病原 学和免疫技术体系方面的研发项目。其次，重大传染病专项培养技术也会在"十四五"期间尽早投入。另 外，目前一些疫苗方面的突破得益于企业的储备。 ...

Core Viewpoint - The company, Liaoning Chengda, has decided to permanently suspend operations at Xinjiang Baoming Mining Co., Ltd. and will not provide further large cash injections, focusing instead on attracting strategic investors and shifting its focus towards core industries like biomedicine [1] Group 1: Company Strategy and Management - The new management team, elected in February, is actively optimizing the financing structure and controlling funding costs to ensure stable operations across all business segments [2] - The company has issued short-term financing bonds with decreasing interest rates, indicating a successful reduction in financing costs [2] - The management aims to enhance the company's core competitiveness and sustainable development through non-public issuance of exchangeable bonds [3] Group 2: Financial Performance and Investments - The company has seen significant growth in investment income from its holdings in Guangfa Securities and China Insurance, with year-on-year increases of 53.19% and 143.94%, respectively [4] - The capital market has rebounded, contributing to the increase in asset values and overall financial performance [4] Group 3: Focus on Biomedicine - The company has partnered with the Chinese Academy of Sciences to establish an AI-based vaccine research laboratory, aiming to enhance innovation in vaccine development [6] - Ongoing collaborations with the Chinese Academy of Microbiology focus on infectious disease prevention, with several vaccine candidates in various stages of clinical trials [7] - The company is expanding its vision beyond human vaccines to explore early-stage biopharmaceutical technologies and potential mergers and acquisitions to create a second growth curve [7]

本轮融资由领航新界资本领投。本轮所募资金将主要用于加速公司化学合成QS-21等佐剂原料的GMP生 产基地建设，推动在全球范围内的商业化进程，并进一步拓展公司在新型佐剂领域的研发管线。 11月21日，重庆百达信生物技术有限公司（以下简称"百达信生物"或"公司"）宣布已成功完成超过3000 万元人民币的Pre-A轮融资。 ...

经济观察网 据威斯克生物微信公众号消息，近日，由威斯克生物联合四川大学华西医院自主研发的痤 疮治疗性疫苗，正式获得中国国家药品监督管理局（NMPA）新药临床试验申请（IND）批准，成为我 国首款进入临床阶段的痤疮治疗性疫苗。威斯克生物是一家创新型生物医药企业，2021—2025年连续四 年成功入选独角兽企业，在北京、成都和广州设立了研发、生产和销售机构。 ...

大赛虽已收官，但创新创业的故事才刚刚启幕。从7146个项目中脱颖而出的优秀团队，正手握技术的利 刃，怀揣改变世界的热情，成为湾区建设中最具活力的"新星力量"。 为持续讲述这些动人的创新篇章，本系列报道推出专题《湾区创talk·一期一会》。以"一期一会"为主 线，我们将一次次走近大赛获奖项目，记录思想的碰撞、技术的迭代与梦想的生长——创业菁英们用人 工智能重塑生产力，以生物医药守护人类健康，借智能装备升级传统行业，凭文化创意点亮美好生活。 从院士领衔的尖端平台，到青年学子的奇思妙想；从意向融资过亿的"航母项目"，到扎根田野的智 能"农夫"……每一次相遇，都是对创新精神的致敬；每一次"一期一会"，都是湾区未来的注脚。 在刚刚落幕的2025年粤港澳大湾区创业大赛的舞台上，一个来自香港的艾滋病治疗性核酸疫苗项目脱颖 而出。医克生物行政总裁兼联合创始人金侠在进行了12分钟的路演与答疑后，项目不仅斩获大赛生物医 药赛道特等奖，更收获了四家投资机构总额8500万元的意向投资。 其中，意向出资最高的川商基金当场与团队签署投资意向书。两周之后，双方在上海进行了近4小时的 闭门会谈，继续深入了解。这一项目的独创性在哪里？从香港走 ...

Core Insights - The 2025 Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition showcased innovative projects, with a focus on technology and future industries [2] - The competition highlighted the collaboration between Hong Kong and mainland China in fostering biotech innovations, particularly in the context of the ICVAX HIV therapeutic vaccine project [4][8] Company Highlights - The ICVAX project, developed by MedK Bio, is based on patented technology from the University of Hong Kong, enhancing immune response against HIV [4][8] - MedK Bio secured a total of 85 million yuan in investment intentions from four institutions during the competition, with the highest single offer reaching 60 million yuan [7][13] - The project has achieved a 100% follow-up rate in its clinical trials, with safety and immunogenicity data exceeding expectations [4][5] Industry Collaboration - The project exemplifies the synergy between Hong Kong's research capabilities and mainland China's clinical resources, with Shenzhen Third People's Hospital serving as the primary clinical trial site [8][9] - MedK Bio's development path illustrates the integration of resources across the Greater Bay Area, enhancing the region's biotech innovation landscape [14] Future Prospects - MedK Bio plans to advance to Phase II clinical trials for ICVAX and expand its portfolio to include treatments for other infectious diseases and cancers, aiming for commercialization by 2028 [13][14] - The company is also collaborating with the National Manufacturing Innovation Center based in Shenzhen to establish a new laboratory [13]

荷牧生物由国内先进的技术开发团队及实力强大的管理团队共同打造，是国内首家专注于动物新型 mRNA疫苗创新型研发企业。致力于新型动物病毒性传染病mRNA疫苗研发，通过不断的产品创新，提 供更安全更有效的新型疫苗。 同时开展精准的动物传染病体外检测试剂研发，建立全面完善的病原检 测及预防解决方案，为全国乃至世界的畜牧业健康发展提供保障。 | 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-11-02 | 中美绿色基金 | 未披露 | A轮 | | 2024-04-22 | 临空集团 | 未披露 | 股权融资 | | 2023-12-11 | 宽带智汇母基金 | 未披露 | Pre-A轮 | | 2022-12-13 | 依依股份 中美绿色真金 | 1550万人民币 | 天使+ | | | 个人投资者 | | | | | 英诺天使基金 | | | | 2022-10-20 | 泰有其余 | 未披露 | 天使轮 | | | 水木清华校友墓金 | | | 证券之星消息，根据天眼查APP于11月2日公布的信息整理，北京荷牧生物科技有限公司A轮融资，融 ...

Core Viewpoint - The report indicates that Beijing Kanglwei Biological Technology Co., Ltd. has shown significant revenue growth while still facing losses, marking a transition in its financial performance and business strategy [1] Financial Performance - As of the end of September, the company achieved total revenue of approximately 1.2763 million, representing a year-on-year increase of 106.53% [1] - The company reported a net loss of about 229 million, although this reflects a year-on-year reduction of 16.6% [1] - The net profit growth of 16.6% for the current quarter marks the first time in three years that the company has shifted from negative to positive growth in this metric [1] Business Overview - Founded in 2008, the company focuses on innovative vaccine research and industrialization, positioning itself as a high-tech enterprise [1] - It is recognized as a leader in HPV vaccine research in China, boasting the most comprehensive HPV vaccine product portfolio globally, including three-valent, nine-valent, and fifteen-valent vaccines [1] - The company transitioned from biopharmaceutical research to commercialization, indicating a strategic shift in its business model [1] Market Position - The company successfully listed on the Beijing Stock Exchange on March 15, 2023, under the fourth set of unprofitable standards, making it one of the few companies to do so [1] - It is also the first company to apply for dual listing on both the Beijing and Hong Kong stock exchanges [1]

Core Viewpoint - 百克生物 is committed to innovation-driven development in the booming global biopharmaceutical industry, with a well-structured and diverse research pipeline that enhances its competitive edge [1][2]. R&D Strategy - The company has established a tiered R&D strategy focusing on "upgrading, filling gaps, and innovative breakthroughs," creating a product matrix that addresses health needs across all demographics [1][3]. - The R&D model includes a "production generation, R&D generation, and reserve generation" approach, ensuring a comprehensive layout from mature product production to cutting-edge technology reserves [2]. Key Products and Pipeline - Core products in the "production generation" include varicella vaccine, nasal spray influenza vaccine (both freeze-dried and liquid forms), and attenuated live vaccine for herpes zoster, which support the company's growth [2]. - "R&D generation" products, such as acellular DTP vaccine and adjuvanted influenza vaccines, are currently in clinical stages, while "reserve generation" products like HSV-2 mRNA vaccine and Alzheimer's therapeutic vaccine lay the foundation for long-term development [2]. Technological Platforms - The company has developed five core technology platforms: virus large-scale culture, formulation and adjuvant technology, genetic engineering, bacterial vaccine technology, and mRNA vaccine technology, supporting 13 vaccine projects and 3 monoclonal antibodies for infectious disease prevention [3]. - The company has achieved breakthroughs in mRNA vaccines and recombinant protein vaccines, with proprietary adjuvants already applied in various vaccine formulations [3]. Recent Achievements - In the first ten months of the year, the company received one production license for liquid nasal spray influenza vaccine and submitted five clinical trial applications for adjuvanted influenza vaccines, with four already approved [3][4]. - The company is developing a multi-component HSV-2 mRNA vaccine that enhances immune response and has initiated Phase I clinical trials, which could significantly enrich its product pipeline [4]. - The Alzheimer's therapeutic vaccine is in preclinical research, showing promising safety and immunogenicity, with potential applications for early treatment and prevention in at-risk populations [4].